The Ohio State University College of Medicine, Columbus, OH, USA.
Department of Radiation Oncology, Arthur G. James Hospital/Ohio State Comprehensive Cancer Center, Columbus, OH, USA.
Exp Mol Pathol. 2022 Oct;128:104813. doi: 10.1016/j.yexmp.2022.104813. Epub 2022 Jul 25.
Glioblastoma (GBM) patients currently face poor survival outcomes with an average survival period of <15 months, while only 3-5% of patients survive longer than 36 months. Although the mechanisms of tumorigenesis are still being elucidated, miRNAs are promising candidates to explore as novel and prognostic biomarkers in GBM. In this study, we identified the association between miR-575 expression and overall survival (OS) of primary GBM patients and undertook functional studies to discern the contribution of miR-575 to GBM tumorigenesis.
Total RNAs were isolated from 254 FFPE GBM tumor samples and miR expression was assayed (simultaneously) using NanoString Technologies. To determine the association between miR-575 and patients' prognosis, Kaplan-Meier, univariable and multivariable Cox regression analyses were performed. Cell proliferation, colony formation, migration assays were conducted to investigate the function of miR-575 in vitro and in vivo. In silico target gene network analysis was performed to identify the putative targets of miR-575 in GBM, which were further verified by luciferase reporter assay, as well as qPCR and immunoblotting.
Our clinical data (n = 254) show that miR-575 is associated with worse GBM OS by univariable analysis (UVA, HR = 1.27, p-value<0.001) and multivariable (MVA, HR = 1.23, p = 0.007) analysis incorporating critical clinical variables. Functional studies indicated that overexpression of miR-575 significantly increased cell proliferation and migration of GBM cells in vitro, as well as tumor growth in vivo. Subsequent in silico target gene network and mechanistic studies identified CDKN1B/p27 and PTEN, as potential targets of miR-575 in GBM. MicroRNA-575 can also regulate the activity of AKT and ERK pathways in GBM.
miR-575 has prognostic value in GBM, with higher expression associating with worse OS of patients, and contributes to GBM tumorigenesis by regulating multiple signaling pathways in GBM.
胶质母细胞瘤(GBM)患者的平均生存时间<15 个月,目前生存预后较差,仅有 3-5%的患者生存时间超过 36 个月。尽管肿瘤发生的机制仍在阐明之中,但 microRNAs 作为 GBM 新型且预后相关的生物标志物极具研究前景。在本研究中,我们确定了 miR-575 的表达与原发性 GBM 患者总生存期(OS)之间的关联,并进行了功能研究以探究 miR-575 对 GBM 肿瘤发生的作用。
从 254 例 GBM 肿瘤 FFPE 样本中提取总 RNA,同时使用 NanoString 技术进行 miR 表达分析。为了确定 miR-575 与患者预后之间的关系,我们进行了 Kaplan-Meier、单变量和多变量 Cox 回归分析。通过细胞增殖、集落形成和迁移实验在体外和体内研究了 miR-575 的功能。通过计算靶基因网络分析鉴定了 GBM 中 miR-575 的潜在靶基因,并通过荧光素酶报告基因实验以及 qPCR 和免疫印迹实验进行了进一步验证。
我们的临床数据(n=254)显示,miR-575 通过单变量分析(UVA,HR=1.27,p 值<0.001)和包含关键临床变量的多变量分析(MVA,HR=1.23,p=0.007)与 GBM 的 OS 较差相关。功能研究表明,miR-575 的过表达显著增加了 GBM 细胞的体外增殖和迁移能力,并促进了体内肿瘤的生长。随后的计算靶基因网络和机制研究确定 CDKN1B/p27 和 PTEN 是 GBM 中 miR-575 的潜在靶基因。miR-575 还可以调节 GBM 中 AKT 和 ERK 通路的活性。
miR-575 在 GBM 中具有预后价值,表达水平较高与患者的 OS 较差相关,并通过调节 GBM 中的多条信号通路促进 GBM 肿瘤的发生。